Literature DB >> 12203788

Hemizygous deletions in the HLA region account for loss of heterozygosity in the majority of diffuse large B-cell lymphomas of the testis and the central nervous system.

Ekaterina S Jordanova1, Sietske A Riemersma, Katja Philippo, Micheline Giphart-Gassler, Ed Schuuring, Philip M Kluin.   

Abstract

Loss of heterozygosity (LOH) is a major mechanism for inactivation of tumor-suppressor genes and has been observed in various solid tumors and lymphomas. The human leukocyte antigen (HLA) region is located at chromosome band 6p21.3, and loss or alteration of this region may provide tumor cells with a mechanism to escape from the immune system. We previously identified small homozygous deletions within the HLA class II region in many of the diffuse large B-cell lymphomas (DLCLs) of the central nervous system (CNS) and the testis. In the present study, we focused on the mechanism leading to LOH in the HLA region. Twenty microsatellite markers, of which 12 were specific for HLA, were applied on 11 extranodal DLCLs of the CNS and 28 of the testis. Additionally, fluorescence in situ hybridization with seven HLA-specific probes and a centromere 6-specific probe was performed on 20 cases to study the mechanism of LOH. In contrast to previously published data on spontaneously mutated lymphoblastoid cell lines, intrachromosomal hemizygous deletion, not mitotic recombination, was the major cause of LOH of the HLA region in these lymphomas. However, opposed to data in colorectal cancer, these deletions were rarely (one of nine cases) associated with an interchromosomal rearrangement such as a translocation. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12203788     DOI: 10.1002/gcc.10093

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  16 in total

1.  Increased C-MYC copy numbers on the background of CDKN2A loss is associated with improved survival in nodular melanoma.

Authors:  Denitsa Koynova; Ekaterina Jordanova; Nicole Kukutsch; Pieter van der Velden; Draga Toncheva; Nelleke Gruis
Journal:  J Cancer Res Clin Oncol       Date:  2006-09-15       Impact factor: 4.553

2.  Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions.

Authors:  Lisa M Rimsza; Robin A Roberts; Elias Campo; Thomas M Grogan; Silvia Bea; Itziar Salaverria; Andreas Zettl; Andreas Rosenwald; German Ott; H Konrad Muller-Hermelink; Jan Delabie; Richard I Fisher; Joseph M Unger; Michael Leblanc; Louis M Staudt; Elaine S Jaffe; Randy D Gascoyne; Wing C Chan; Dennis D Weisenburger; Timothy Greiner; Rita M Braziel; Thomas P Miller
Journal:  Blood       Date:  2005-10-20       Impact factor: 22.113

3.  Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival.

Authors:  Robin A Roberts; George Wright; Andreas R Rosenwald; Marina A Jaramillo; Thomas M Grogan; Thomas P Miller; Yvette Frutiger; Wing C Chan; Randy D Gascoyne; German Ott; H Konrad Muller-Hermelink; Louis M Staudt; Lisa M Rimsza
Journal:  Blood       Date:  2006-03-16       Impact factor: 22.113

4.  Differential expression of Toll-like receptor (TLR) and B cell receptor (BCR) signaling molecules in primary diffuse large B-cell lymphoma of the central nervous system.

Authors:  Ariz Akhter; Noraidah Masir; Ghaleb Elyamany; Kean-Chang Phang; Etienne Mahe; Ali Matar Al-Zahrani; Meer-Taher Shabani-Rad; Douglas Allan Stewart; Adnan Mansoor
Journal:  J Neurooncol       Date:  2014-11-13       Impact factor: 4.130

Review 5.  New approaches in primary central nervous system lymphoma.

Authors:  Eleanor Fraser; Katherine Gruenberg; James L Rubenstein
Journal:  Chin Clin Oncol       Date:  2015-03

6.  [Extranodal diffuse large B-cell lymphoma--an organotypic disease?].

Authors:  G Ott; A Rosenwald
Journal:  Pathologe       Date:  2007-02       Impact factor: 1.011

7.  How I treat CNS lymphomas.

Authors:  James L Rubenstein; Neel K Gupta; Gabriel N Mannis; Amanda K Lamarre; Patrick Treseler
Journal:  Blood       Date:  2013-08-20       Impact factor: 22.113

8.  Mutations in the HLA class II genes leading to loss of expression of HLA-DR and HLA-DQ in diffuse large B-cell lymphoma.

Authors:  Ekaterina S Jordanova; Katja Philippo; Marius J Giphart; Ed Schuuring; Philip M Kluin
Journal:  Immunogenetics       Date:  2003-05-17       Impact factor: 2.846

Review 9.  Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma.

Authors:  M Ponzoni; S Issa; T T Batchelor; J L Rubenstein
Journal:  Ann Oncol       Date:  2013-11-20       Impact factor: 32.976

Review 10.  Progress in central nervous system lymphomas.

Authors:  Chia-Ching Wang; Julia Carnevale; James L Rubenstein
Journal:  Br J Haematol       Date:  2014-05-16       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.